FDA decision: Gedatolisib by Celcuity Inc. (July 2026)

Prediction market odds on Kalshi reflect aggregated trader expectations and often diverge from traditional analyst consensus. While sell-side equity analysts may issue coverage with approval probability estimates based on clinical trial data and regulatory precedent, prediction markets incorporate real-time sentiment and financial incentives. Comparing Kalshi implied odds to published analyst reports and biotech research notes can reveal whether the market is pricing in more optimism or caution than the consensus view on Gedatolisib's regulatory pathway.

On Kalshi, prices reflect that venue's order book, liquidity, and how traders price the outcome right now. On Kalshi, the Gedatolisib FDA decision market is priced as a binary contract reflecting approval or non-approval outcomes. Traders buy and sell shares at prices between 0 and 100 cents, with the implied probability derived from the current market price. Volume and open interest on Kalshi indicate the level of conviction and liquidity among participants betting on the FDA's determination. Price movements respond to clinical updates, regulatory communications, and shifts in trader positioning as the July 2026 decision date approaches.

The market is scheduled to resolve by Aug 1, 2026, aligned with the expected FDA decision window for Gedatolisib. Resolution is determined by the actual FDA action—whether the agency issues an approval, rejection, or other definitive determination on Celcuity's application. The specific regulatory decision letter or public FDA announcement serves as the authoritative source for market settlement, translating the real-world outcome into a binary contract resolution on the prediction market platform.

Key catalysts include Celcuity's clinical trial data releases, FDA meeting minutes or advisory committee feedback, regulatory guidance letters, and competitive approvals in the same therapeutic space. Earnings calls and investor updates from Celcuity may contain material information about the regulatory timeline or discussions with the FDA. Broader biotech sentiment, changes in FDA review standards, and any safety or efficacy signals emerging from ongoing studies could shift market pricing. Media coverage of the drug candidate and analyst commentary also influence trader positioning ahead of the July 2026 decision.